COMMUNIQUÉS West-GlobeNewswire

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
13/05/2025
CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI ® clinical production at the Tech Lane facility Received positive [...]
Microbix & Aurevia Introduce Novel EQA Scheme
13/05/2025
Pilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a [...]
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
13/05/2025
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) [...]
Algernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan Technology
13/05/2025
First Clinic Targeted to Open Q4, 2025 in the U.S. VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a [...]
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity
13/05/2025
• This model demonstrates that central inhibition of CB1 is not required for weight loss • Anti-CB1 inhibiting antibody, nimacimab, showed greatest peripheral restriction compared with monlunabant and rimonabant, small [...]
GenVivo Highlights GEN2 Phase 1 Data and GEN-1013 Preclinical Data at the 2025 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting
13/05/2025
GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and expansion trial. GEN-1013 was studied in aggressive murine cancer models using both IV and IT [...]
Immatics Announces First Quarter 2025 Financial Results and Business Update
13/05/2025
IMA203 PRAME Cell Therapy: Randomized-controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing and expected to complete enrollment in 2026 IMA203 PRAME Cell Therapy: Phase 1b clinical trial [...]
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
13/05/2025
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology for [...]
New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy
13/05/2025
Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average [...]
Arbor Biotechnologies to Present Preclinical Data for ABO-101 in PH1 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
13/05/2025
– Data from oral presentation supported ABO-101 IND and CTA approval for clinical assessment in primary hyperoxaluria type 1 (PH1) in the Phase 1/2 redePHine study in US and UK ( NCT06839235 ) – Preclinical data [...]
NewBiologix Presents New Data at ASGCT on the Effective Manufacturing of rAAV-based therapeutics
13/05/2025
LAUSANNE, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- NewBiologix, a next-generation biotechnology company pioneering the future of recombinant adeno-associated virus (rAAV) production through a unique DNA-based [...]
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
13/05/2025
~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~ ~ PEDMARQSI Now [...]
The Ensign Group to Present at the 2025 RBC Capital Markets Global Healthcare Conference
13/05/2025
SAN JUAN CAPISTRANO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Ring Therapeutics Presents New Data on its AnelloBricks® Manufacturing Platform at the 28th Annual American Society of Gene & Cell Therapy Conference
13/05/2025
AnelloBricks is a promising in vitro approach to producing a new class of functional viral vectors, offering dramatic advantages in manufacturing scalability and cost compared to existing vector systems Payload [...]
Transactions of Managers and Closely Associated Persons
13/05/2025
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 210,000 shares [...]
RevoluGen and ProteoQuest Join Forces to Bring Fire Monkey HMW-DNA Extraction to China and Asia Pacific’s Fast Growing DNA Sequencing-based Genomics Markets
13/05/2025
HADFIELD, United Kingdom and HONG KONG, May 13, 2025 (GLOBE NEWSWIRE) -- UK genomics tools company, RevoluGen Limited and Hong Kong-based life sciences distributor ProteoQuest Technology Co. Ltd are pleased to announce [...]
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025
13/05/2025
EnteroBiotix Presents Positive Data in Liver Cirrhosis at EASL 2025 EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May [...]
TILT Biotherapeutics Announces Closing of USD 25 Million Series B Financing
13/05/2025
Initiates Phase 2 platinum-resistant ovarian cancer trial HELSINKI, May 13, 2025 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (Tiltbio), a clinical-stage biotechnology company developing intravenously delivered cancer [...]
Eleva Appoints Donato Spota as Chief Financial Officer
13/05/2025
Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial [...]

Pages